
Keywords: اصلاح دز; CCMC; Commercial Claims and Medicare; CCI; Charlson Comorbidity Index; del(5q); deletion 5q abnormality; DOT; duration of therapy; DM; dose modification; ESAs; erythropoiesis-stimulating agents; G-CSF; granulocyte colony-stimulating factor; ICD-9-CM; Inte